To obtain documents, log on:
:
Not registered? Register me now
 

Public Higher Education Bulletin

 
University of Illinois at Chicago
SoleSource #607JCM
Announcement of a Sole Source Purchase
Change Order
Published Wednesday October 26, 2016
Vendor: Genzyme Corporation
Change Order Amount: $0

Renewal term correction. The first renewal term should be from 11/26/2016 through 11/25/2017. Corrected renewal term from 11/25/2016 through 11/25/2017 is necessary for consistency with the contract.
The State Purchasing Officer for this procurement is now Aaron M. Finder.
The University award process may be delayed up to thirty days as this award goes through a state approval process.
Renewal Info
Published Tuesday October 11, 2016
Renewal entered into with:
Vendor: Genzyme Corporation
Amount: An estimated $410,000
Renewal: 1st of 2, 10/26/2016 through 10/25/2017
Pricing Changes: 
None
Service/Product Changes: 
None
Sole Source Status: 
Yes remains a sole source.
Potential Future Renewals: $410,000
Comments: Genzyme continues to be the manufacturer and sole source to obtain this product. Purchase of recently FDA-approved biologic agent for the treatment of relapsing multiple sclerosis.
The State Purchasing Officer for this procurement is now Aaron M. Finder.

The University award process may be delayed up to thirty days as this award goes through a state approval process.
Award Info Published Monday November 30, 2015
Awarded to:
Vendor: Genzyme Corporation, Cambridge, MA
Amount: An estimated $410,000
Terms:
An estimated start date of 11/26/2015 through 11/25/2016, 12 months
Renewals:
2 twelve-month
Potential Future Renewals: $820,000
The University award process may be delayed up to thirty days as this award goes through a state approval process.
The hearing has been cancelled
Published Monday November 16, 2015
The hearing has been cancelled since no vendors registered to attend or submitted comments regarding this notice.
First published Friday, October 30, 2015
The University awarded a contract for Lemtrada (alemtuzumab) for MS patient care to Genzyme Corporation, Cambridge, MA, for an estimated $410,000.
Purchase of Lemtrada (alemtuzumab,the newly FDA-approved treatment for Relapsing Multiple Sclerosis.

Genzyme is the manufacturer of this medication and direct purchase from Genzyme is the only method to obtain the product. The product has a Risk Evaluation and Mitigation Strategy (REMS) program, requiring the manufacturer to monitor monthly patient labs for 40 months after treatment. In other words, the patient lab sample testing is a requirement of the Lemtrada REMS. If the patients lab values are unacceptable, the patient may have to reduce dosage, increase interval between doses, or discontinue the treatment all together. None of these scenarios would have any effect on this Sole Source Justification For this reason, the manufacturer has limited the distribution of this product. The product may only be obtained directly from Genzyme and they have no resellers or distributors.
The University has determined that this purchase is only economically available from this source because the items are needed for trial use or testing. Genzyme is the distributor/manufacturer for FDA-approved Lemtrada (alemtuzumab).

For additional information, contact:
John Meehan
University of Ilinois at Chicago
Purchasing Division (M/C 560)
809 South Marshfield Avenue
Chicago, IL 60612-7203
Phone: (312) 413-5961
FAX: (312) 996-2055
State Purchasing Officer - Aaron M. Finder

We will hold a public hearing at the date, time and location specified below, if we receive a request to testify regarding the sole source determination. We will also hold a hearing if any vendor submits a signed statement showing the capability to provide the stated supplies/services at or below the amount indicated.

The public hearing allows any interested party the opportunity to testify for or against the sole source determination as described in this notice. The purpose of the hearing is to receive information from the public in a reasonable manner. Formal rules of evidence will not apply. The hearing officer will produce minutes of the hearing and may record it in order to aid in the production of the minutes. After conclusion of the hearing we will decide whether the sole source determination was appropriate.

We must receive any request to testify and any vendor statement no later than the registration date and time indicated below. If we do not receive a timely request or statement, we will not hold the hearing. We reserve the right to cancel the procurement prior to any scheduled hearing. Please confirm the status of the hearing with the Hearing Contact.

Date:
November 18, 2015
Time:
2:00 PM
Location:
Stratton Building
Room 511
401 S. Spring Street
Springfield, IL

Hearing Contact:
Aaron M. Finder
Phone:(217) 720-7105
Date, time, and location are subject to change and/or cancellation. It is the responsibility of potential participants to confirm these details prior to attendance.

Registration Deadline:
November 13, 2015
Register with:
Aaron M. Finder
Phone:(217) 558-3050
Fax:(217) 558-5407

The State of Illinois has a policy to encourage prospective vendors to hire qualified veterans, minorities, females, persons with disabilities and ex-offenders.

Bulletin Navigation

 
To obtain documents, log on:
Sole Source Justification
  • 607JCMPart1.pdf (309 KB)
Public Hearing Documents
  • 607JCM11_6_15.pdf (305 KB)
  • 607JCMPart2.pdf (61 KB)
  • 607JCMPt2.pdf (61 KB)
Other Public Documents
  • 607JCMrenewal.pdf (103 KB)
  • 607JCMRevisedPart1.pdf (323 KB)